Ocuphire Pharma Inc
NASDAQ:OCUP

Watchlist Manager
Ocuphire Pharma Inc Logo
Ocuphire Pharma Inc
NASDAQ:OCUP
Watchlist
Price: 1.13 USD -3.42% Market Closed
Market Cap: 35.7m USD

Net Margin
Ocuphire Pharma Inc

-85.7%
Current
61%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-85.7%
=
Net Income
-14.1m
/
Revenue
16.5m

Net Margin Across Competitors

No Stocks Found

Ocuphire Pharma Inc
Glance View

Market Cap
35.7m USD
Industry
Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.

OCUP Intrinsic Value
2.09 USD
Undervaluation 46%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-85.7%
=
Net Income
-14.1m
/
Revenue
16.5m
What is the Net Margin of Ocuphire Pharma Inc?

Based on Ocuphire Pharma Inc's most recent financial statements, the company has Net Margin of -85.7%.

Back to Top